- Location
bosutinib
"-
The UK NICE Has Rejected Pfizer's New Chronic Myeloid Leukaemia (CML) Drug
Jul 17, 2013The UK National Institute for Health and Care Excellence (NICE) has rejected Pfizer’s new chronic myeloid leukaemia (CML) drug, Bosulif (bosutinib). NICE chief executive Sir Andrew Dillon said there is evidence to suggest that ...
Tags: Cancer Drug, Medicine
-
Doctors Calls for Lower Cancer Patients' Drugs Price
May 6, 2013If you've ever had trouble affording your medications and wanted to call your doctor on it, here's some encouraging news: Doctors aren't pleased about the prices either. Denouncing "profiteering" by pharmaceutical companies, more than 100 ...
-
EC Granted Conditional Marketing Authorization for Bosutinib Anti-Cancer Drug in The EC
Apr 1, 2013The European Commission (EC) has granted conditional marketing authorization for Pfizer's Bosulif (bosutinib) anti-cancer drug in the European Union (EU). Bosulif is authorized in Europe for the treatment of adult patients with chronic ...
Tags: Pfizer Bosulif, cancer drug, drug
-
Pfizer's Bosutinib Received Positive Opinion for The Conditional Marketing Authorization
Jan 22, 2013Pfizer's bosutinib has received positive opinion for the conditional marketing authorization from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The bosutinib positive CHMP opinion is concerned with ...
-
FDA Approved Pfizer's Bosulf to Treat Adult Patients with PH+ CML
Dec 5, 2012US Food and Drug Administration (FDA) has approved Pfizer's Bosulf (bosutinib) to treat adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) (CML) with resistance to prior therapy. Bosulif is a ...
Tags: bosulf, bosutinib, kinase inhibitor, Philadelphia chromosome-positive
Related Products
-
Sonwu Supply Raw Powder Pure Bosutinib Powder Bosutinib
-
Good Quality Bosutinib CAS 380843-75-4 for Chronicmyeloid Leukemia
-
CAS 380843-75-4 Bosutinib Pharmaceutical Raw Material
-
for Antineoplastic Agents Anticancer Bosutinib CAS 380843-75-4 for Chronicmyeloid Leukemia Inc28060
-
Bosutinib 380843-75-4
-
Supply 99% Raw Material Bosutinib Pharmaceutical Powder CAS 380843-75-4 Bosutinib
